Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04512365 · ClinicalTrials.gov registry record · Early Phase 1
Reward and Drug Effects on Mood and Brain Response
A Early Phase 1 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 141
- Enrollment target
NCT04512365: Completed Early Phase 1 study, sponsored by University of Illinois at Chicago.
NCT04512365 is a Early Phase 1 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 141 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (166% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04512365, a Early Phase 1 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 141 participants
- Enrollment target
Study Summary
The goal of the study is to better understand the neural mechanisms underlying the rewarding, reinforcing properties of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, among healthy young adults.
Primary Outcome
Participants will complete the Doors task during electroencephalogram (EEG) capturing the RewP, with higher values indicating greater neural response to reward
Interventions
- DRUG THC
- DRUG Placebo oral capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2021-03-16 |
| Est. Completion | 2025-05-02 |
| Phase | Early Phase 1 |
What the finished NCT04512365 record still lists
NCT04512365 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (166% higher).
The record links to 0 conditions, and to 2 interventions - of which THC is the first listed.
NCT04512365 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04512365 about?
NCT04512365 is a clinical study titled "Reward and Drug Effects on Mood and Brain Response". The goal of the study is to better understand the neural mechanisms underlying the rewarding, reinforcing properties of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, among healthy young adults.
What is the current status of trial NCT04512365?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 141 participants. The study started on 2021-03-16. Estimated completion is 2025-05-02.
What interventions are being tested in trial NCT04512365?
The interventions under investigation include: THC (DRUG), Placebo oral capsule (DRUG).
Who is sponsoring clinical trial NCT04512365?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04512365's enrollment target sits among peer trials
141 116th of 2000 higher than 1,885 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI